Join our LinkedIn PATENTSCOPE users Community Group
反馈
设置

设置

查看申请

1,073 个结果
专利局 all 语言 词根提取 false 单一族成员 true 包括NPL false
只有拥有WIPO帐户才能生成RSS源

保存查询

私人查询仅在您登录后对您可见，而不能在RSS 订阅中使用

查询树

优化选项

专利局
全部
指明检索关键词的语言
词根提取功能可将屈折词还原回词根形式。
例如，fishing、fished、fish 和 fisher 这些词都会还原回词根 fish，
因此检索 fisher 即可获得各种变形的所有结果
仅返回专利族的一个成员
在结果中包括非专利文献

完整查询

IC:A61K33/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

并排视图快捷键

一般快捷键
转到检索输入栏
CTRL + SHIFT +
转到结果（选定结果）
CTRL + SHIFT +
转到详细信息（选定标签）
CTRL + SHIFT +
转到下一页
CTRL +
转到上一页
CTRL +
结果（首先，执行“转到结果”）
转到下一个结果/图像
/
转到上一个结果/图像
/
向上滚动
Page Up
向下滚动
Page Down
滚动至顶部
CTRL + Home
滚动至底部
CTRL + End
详细信息（首先，执行“转到详细信息”）
转到下一个标签
转到上一个标签

分析

1 / 108
1.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO - 21.10.2021
国际分类 A61K 31/7135
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
31含有机有效成分的医药配制品
70碳水化合物;糖;其衍生物
7135含有重金属的化合物
 申请号 PCT/US2021/027404 申请人 GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 发明人 KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
2.WO/2023/073086IRON OXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO - 04.05.2023
国际分类 A61K 9/51
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
9以特殊物理形状为特征的医药配制品
48胶囊制剂,例如用明胶、巧克力制造的
50微型胶囊
51用于医用配制品纳米胶囊制剂
 申请号 PCT/EP2022/080053 申请人 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS 发明人 BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless a new infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019 2021 coronavirus pandemic. The present invention discloses the use of coated iron oxide nanoparticles (IONPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV, SARS-CoV-2 and MERS-CoV. The iron oxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen, nitrogen and sulfur donor atoms (e.g. dextran, (3- aminopropyl)triethoxysilane or dimercaptosuccinic acid, respectively). The IONPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication, transcription and production of infectious virus. Furthermore, the IONPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
3.WO/2023/073091IRON OXYHYDROXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO - 04.05.2023
国际分类 A61K 33/26
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
33含无机有效成分的医用配制品
24重金属;其化合物
26铁;其化合物
 申请号 PCT/EP2022/080059 申请人 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS 发明人 BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless, a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019-2021 coronavirus pandemic. The present invention discloses the use of coated iron oxyhydroxide nanoparticles (lOHNPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV and SARS-CoV-2 and MERS-CoV. The iron oxyhydroxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen (e.g. sorbitol and sucrose). The lOHNPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication and transcription. Furthermore, the lOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
4.WO/2022/031416COMPOSITIONS AND METHODS FOR PREVENTION OF VIRAL INFECTIONS AND ASSOCIATED DISEASES
WO - 10.02.2022
国际分类 A61K 33/20
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
33含无机有效成分的医用配制品
20元素氯;释放氯的无机化合物
 申请号 PCT/US2021/041682 申请人 MICROPURE, INC. 发明人 JAIPRAKASH, Shewale, G.
Described herein are single-phase multi-component compositions and methods for their use reducing the viral load of infectious viruses on host organisms, including but not limited to Influenza A, Rhinovirus Type 14, Adenovirus Type 5, Herpes Simplex Virus Type 1, Herpes Simplex Virus Type 2, Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2; COVID-19 virus), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), and Human coronavirus 229E. The compositions described herein comprise a combination of an oxidative compound and a buffering system. The methods of use of these compositions as antiviral agents when applied to the oral, nasal, ocular, aural, anal, and urogenital cavities are described. Data shows the compositions to be effective in reducing influenza A and the human coronaviruses. In that regard, the single-phase multi-component compositions and methods for its antiviral use disclosed herein may be offer a single, effective product to combat multiple, concurrent pandemics.
5.WO/2023/079466TREATMENT OF SEQUELAE OF CORONAVIRUS INFECTIONS
WO - 11.05.2023
国际分类 A61K 33/04
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
33含无机有效成分的医用配制品
04硫、硒或碲;其化合物
 申请号 PCT/IB2022/060575 申请人 SULFAGENIX, INC. 发明人 GOJON-ZORRILLA, Gabriel
The present invention features compositions and methods for treating sequelae of coronavirus infection, e.g., betacoronavirus. The present invention features a method of treating or preventing one or more sequelae of a coronavirus infection. The method includes administering to the subject a pharmaceutical composition including elemental alpha sulfur, highly polar components, and a pharmaceutically acceptable excipient in an amount and for a duration sufficient to treat or prevent the one or more sequelae of the coronavirus infection.
6.20220016053Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US - 20.01.2022
国际分类 A61K 31/137
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
31含有机有效成分的医药配制品
13胺类,例如金刚烷胺
135有芳环的,例如美沙酮
137芳基烷基胺,例如苯丙胺、肾上腺素、沙丁胺醇、麻黄碱
 申请号 17357388 申请人 ZOGENIX INTERNATIONAL LIMITED 发明人 Bradley S. Galer

Provided is a method of treating a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising: determining the patient has been infected with SARS-CoV-2; and administering to the patient a therapeutically effective dose of fenfluramine.

7.WO/2023/033753FOOD SUPPLEMENT WITH ANTIOXIDANT/ ANTIPROLIFERATIVE PROPERTIES
WO - 09.03.2023
国际分类 A61K 36/282
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
36含有来自藻类、苔藓、真菌或植物或其派生物,例如传统草药的未确定结构的药物制剂
18被子植物亚门
185双子叶植物纲
28紫菀科或菊科(紫菀或向日葵科),例如甘菊,小白菊,耆草或松果菊属或紫锥花属
282艾属,例如苦艾或三齿蒿
 申请号 PCT/TR2021/050883 申请人 ERDEM ÜNLÜ, Gülten 发明人 ERDEM ÜNLÜ, Gülten
The present invention relates to a food supplement with antioxidant/antiproliferative properties that is used in the treatment of COVID-19 coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), contains artemisia annua, distilled water, colloidal silver water and Olea Europaea (olive leaf oil extract).
8.WO/2023/056260METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2
WO - 06.04.2023
国际分类 A61K 33/242
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
33含无机有效成分的医用配制品
24重金属;其化合物
242金;其化合物
 申请号 PCT/US2022/077110 申请人 ARIZONA BOARD OF REGENTS ON BEHALF OFARIZONA STATE UNIVERSITY 发明人 WANG, Chao
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
9.WO/2023/001814COMPOSITION FOR USE IN THE PREVENTION OF SEVERE FORMS OF VIRAL INFECTIONS DUE TO BETACORONAVIRUS
WO - 26.01.2023
国际分类 A61K 31/155
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
31含有机有效成分的医药配制品
13胺类,例如金刚烷胺
155脒NCN,例如胍、异脲(HNC(OH)NH2),异硫脲(NHC(SH)-NH2)
 申请号 PCT/EP2022/070184 申请人 CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES 发明人 CORBEAU, Pierre
The present invention concerns a composition comprising an Angiotensin receptor 1 (AT1) inhibitor and one or more other active compounds selected from the group consisting of antioxidants, caspase inhibitors, and mixtures thereof, for use as a drug in subjects in need thereof, for preventing and/or treating viral infections due to at least one betacoronavirus, in particular for preventing severe forms of viral infections due to betacoronavirus, in particular COVID-19 due to SARS-CoV-2.
10.WO/2021/207178SILVER NANOPARTICLES FOR USE IN INHIBITING AND TREATING CORONAVIRUS INFECTION
WO - 14.10.2021
国际分类 A61K 9/08
A人类生活必需
61医学或兽医学;卫生学
K医用、牙科用或梳妆用的制剂
9以特殊物理形状为特征的医药配制品
08溶液
 申请号 PCT/US2021/025942 申请人 AGARWAL, Ankit 发明人 AGARWAL, Ankit
The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).
# -